IP Library Granted Patent US 10,086,064
Granted Patent B2
US 10,086,064 · App. 15/302,630 · Granted Oct 2, 2018

Vaccine compositions

Inventor: Jeffrey Drew (Sussex, GB)
Assignee: Stabilitech Biopharma Ltd
A61K39/145A61K9/0019A61K9/19A61K31/198A61K39/12A61K39/39A61K47/186A61K47/26C12N7/00A61K2039/51A61K2039/5252A61K2039/55505A61K2039/55511C12N2760/16134C12N2760/16171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,086,064
App. No.
15/302,630
Granted
Oct 2, 2018
Kind
B2
Abstract

The present invention relates to the use of an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof: wherein: R 1 represents C 1-6 alkyl; R 2 represents hydrogen or C 1-6 alkyl; and R 3 represents C 1-6 alkyl, for increasing the immunogenicity of an influenza antigen, which use comprises (a) freezing, (b) heat-treating, and/or (c) freeze-drying an aqueous composition comprising the influenza antigen and the excipient.

Claims (11)

1. A method for increasing the immunogenicity of an influenza antigen, said method comprising heat-treating an aqueous composition at 35° C. to 80° C. for 1 hour or more, the aqueous solution comprising the influenza antigen and an excipient which is a compound of formula (I) or a physiologically acceptable salt or ester thereof:

wherein:

R 1 represents hydrogen or C 1-6 alkyl;

R 2 represents C 1-6 alkyl; and

R 3 represents C 1-6 alkyl; wherein the immunogenicity of the influenza antigen is increased during the heat-treating.

2. The method according to claim 1 , in which the compound of formula (I) is dimethylglycine or trimethylglycine.

3. The method according to claim 2 , in which the compound of formula (I) is dimethylglycine.

4. The method according to claim 1 , in which the aqueous composition further comprises one or more sugars.

5. The method according to claim 4 , in which the one or more sugars are sucrose and raffinose.

6. The method according to claim 1 , in which the aqueous composition further comprises an adjuvant.

7. The method according to claim 6 , in which the adjuvant is an aluminium salt adjuvant.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: STABILITECH BIOPHARMA LTD
To: IOSBIO LTD
Reel/Frame 056065/0883 →
CHANGE OF NAME Recorded Jun 19, 2018
From: STABILITECH LTD.
To: STABILITECH BIOPHARMA LTD
Reel/Frame 046129/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2017
From: DREW, JEFFREY
To: STABILITECH LTD.
Reel/Frame 041565/0299 →
Priority Claims (1)
GB 1406569.2 · Apr 11, 2014 · national
Continuity (1)
Related Publication 20170021008A1 · Jan 26, 2017
Cited By (1)
US 12,251,438